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It was previously shown in the PC-295 xenograft that
the number of chromogranin A (CgA)-positive neu-
roendocrine (NE) cells increased after androgen with-
drawal. NE cells did not proliferate and differentiated
from G0-phase-arrested cells. Here we further charac-
terized NE differentiation, androgen receptor status,
and apoptosis-associated Bcl-2 expression in the PC-
295 model after androgen withdrawal to assess the
origin of NE cells. PC-295 tumor volumes decreased
by 50% in 4 days. Intraperitoneal bromodeoxyuridine
(BrdU) incorporation and MIB-1 labeling decreased to
0%, and the apoptosis was maximal at day 4. Andro-
gen receptor expression and prostate-specific antigen
(PSA) serum levels decreased rapidly within 2 days.
The number of NE cells increased 6-fold at day 4 and
30-fold at day 7. Five and ten percent of the CgA-
positive cells were BrdU positive after continuous
BrdU labeling for 2 and 4 days, respectively. How-
ever, no MIB-1 expression was observed in CgA-pos-
itive cells. NE cells expressed the regulated secretory
pathway marker secretogranin III but were negative
for androgen receptor and Bcl-2. Bcl-2 expression did
increase in the non-NE tumor cells. In conclusion,
androgen withdrawal leads to a rapid PC-295 tumor
regression and a proliferation-independent induction
of NE differentiation. The strictly androgen-indepen-
dent NE cells that were still present after 21 days
differentiated mainly from G0-phase-arrested cells.
(Am J Pathol 1999, 154:543–551)
Neuroendocrine (NE) cells form an androgen-indepen-
dent subfraction of the prostate.1 NE cells have been
localized in nearly all clinical prostatic adenocarcinoma
with different expression patterns.2–8 These cells pro-
duce various growth-modulating neuropeptides in a
paracrine or autocrine way.9–15
Possible roles for NE cells in the prostate may be
regulation of homeostasis and secretion of prostatic fluid,
either actively or passively. NE cells can be identified by
routine electron microscopy (dense core granules) or by
immunohistochemistry with specific antibodies against
secreted products, for example, serotonin,16 or secre-
tion-associated proteins, such as chromogranin A
(CgA),17–19 which is a marker for neuroendocrine differ-
entiation. NE cells are considered to be nonproliferating
cells and do not express the androgen receptor20 and
are therefore probably unaffected by androgen depriva-
tion. Consequently, they will not undergo apoptosis under
such circumstances. Therefore, it is relevant to assess
whether or not CgA-positive cells co-express the anti-
apoptotic oncogene Bcl-2.21 Moreover, NE cells show a
heterogeneous cytokeratin expression pattern as there
are basal, luminal, and intermediate NE cell types16,22,23
and are often found near Bcl-2-positive prostate cancer
cells.24,25
The single expression of CgA is not the only requisite
for the determination of NE differentiated cells as there
exists a regulated secretory pathway (RSP) in NE cells26
next to the lysosomal and an exocrine constitutive path-
way. Along the RSP pathway, secretion and processing
of bioactive neuropeptides and growth hormones, such
as insulin and glucagon in the pancreas,27,28 are regu-
lated. The RSP consists of a sequence of processes
linked from transcription/translation of various factors to
final secretion of neuropeptides at the plasma membrane
from secretory granules.29 Different markers can be iden-
tified, such as granular markers secretogranin III (SGIII)
and secretogranin V (7B2),30–32 peptidylglycine a-ami-
dating monooxygenase (PAM),33,34 the processing en-
zymes prohormone convertase 1 and 2 (PC-1 and -2),
and carboxy peptidase E. Evaluation of these specific
markers of the RSP is ongoing in Xenopus laevis, lung and
prostate cancer.35,36
The number of prostate cancer cases still increases,
and the search for a curative therapy for metastasized
cancer continues. NE cells have been found in most
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prostatic adenocarcinomas, and the role of NE cells in
the progression to androgen-independent growth is still
unclear. Fundamental questions related to a possible role
for NE differentiation in the progression of prostate can-
cer can be solved only by using representative prostate
cancer models with NE differentiation. Several groups
have recently been developing tumor models as both in
vitro cell lines37 and in vivo xenografts.38–40 NE differen-
tiation has been studied in a panel of 11 in vivo human
prostate cancer xenograft models. Some models do not
express the NE phenotype, and PC-324 and PC-346 lose
their NE phenotype after a few passages in nude mice.41
The PC-295 and PC-310 models are androgen-depen-
dent models of which a part of the cells constitutively
show the NE phenotype. Therefore, these two models are
very suitable for studying NE differentiation in prostate
cancer and the role that NE cells may play in the pro-
gression of prostate cancer. In both the PC-295 and
PC-310 models, androgen deprivation leads to an in-
creased number of NE cells. In a previous study with the
androgen-dependent PC-295 model,41 tumors continu-
ously labeled with the S-phase marker bromodeoxyuri-
dine (BrdU) for 2 days before castration showed no dou-
ble labeling of NE cells after castration with BrdU. This
shows that the increased NE phenotype is not induced
before castration. Absence of BrdU and another prolifer-
ation marker, MIB-1, shows that NE cells are not prolifer-
ating and are, thus, G0-phase-arrested cells before an-
drogen withdrawal. However, it cannot totally be
excluded that proliferation occurring after androgen with-
drawal is responsible for the increase in NE differentiation
in the PC-295 model.
In this study, we further looked for the origin of NE cells
by focusing on the kinetics of the process of NE differ-
entiation. Furthermore, we characterized changes in ap-
optosis and subpopulations of prostatic epithelial cells as
marked by their expression of CgA, SGIII, growth-modu-
lating neuropeptides, androgen receptor, and Bcl-2 after
androgen withdrawal in the PC-295 model both shortly
after castration and after prolonged androgen deprivation.
Materials and Methods
PC-295 Xenograft Model
The nude mouse human prostate cancer xenograft model
PC-295 was established from a pelvic lymph node me-
tastasis.40,42 The tumors usually grow with a doubling
time of approximately 14 days and a lag phase of 2 to 3
months. The model represents a strictly androgen-de-
pendent and moderately differentiated tumor, histologi-
cally organized in solid sheets and micro-acini. In short,
PC-295 tumors were implanted subcutaneously at both
shoulders of intact nude NMRI males, obtained from the
breeding colony of the Erasmus University Center for
Animal Research. Optimal growth conditions were
reached by supplementation of PC-295-transplanted
mice with testosterone implants, as previously de-
scribed.43 The subcutaneous tumors developed within 2
to 3 months and were grown up to a maximal volume of
2000 mm3. Tumor volume changes were followed weekly
by two perpendicular diameter measurements (D1 and
D2), after which the volume was calculated from the
formula: V 5 (P/6)(D1 3 D2)3/2.
Castration Experiments with the PC-295 Human
Prostate Cancer Xenograft Model
Two consecutive castration experiments were performed
with 39 testosterone-supplemented PC-295-bearing male
NMRI mice in total. Androgen withdrawal was performed
by castrating the mice under hypnorm anesthesia (Jans-
sen Pharmaceuticals, Oxford, UK) and by removing the
silastic implant. The mice received BrdU to check the
effect of androgen withdrawal on the proliferative activi-
ties in the PC-295 tumor tissue. One group of mice re-
ceived BrdU (1 mg/ml) intraperitoneally (IP) as standard
labeling for 1 hour before sacrifice. The second group
received BrdU (30 mg/ml) via subcutaneously inserted
osmotic Alzet micropumps (Alzet 1007D, Alza Corp., Palo
Alto, CA) having a flow rate of 0.5 ml/hour as of the
moment of castration until sacrifice. Three mice were
sacrificed at each time point after castration. For the first
experimental set-up, these time points were 0, 0.5, 1, 1.5,
2, 4, 7, 14, and 21 days, whereas in the second set-up,
mice received BrdU for 0, 1.5, 2, 4, and 7 days after
castration.
After blood samples were taken for determining serum
prostate-specific antigen (PSA) levels, mice were sacri-
ficed. Tumor volumes were measured, and tumors were
removed. The tumors were cut into small pieces that were
either fixed in 4% buffered formalin and paraffin embed-
ded for immunohistochemical analysis or snap-frozen in
liquid nitrogen and stored at 280°C for biochemical anal-
ysis. The paraffin-embedded material was processed
routinely for hematoxylin and eosin (H&E) staining.
Immunohistochemistry
To identify the fraction of cells expressing the NE pheno-
type, paraffin-embedded tissue sections of the PC-295
xenografts were stained immunohistochemically with an-
tibodies against CgA (clone LK2H10, ICN Pharmaceuti-
cals, Aurora, OH) and SGIII (rabbit polyclonal antibody;
Department of Animal Physiology, University of Nijme-
gen).44 For identification of the proliferative capacity, tis-
sue sections were stained with antibodies against BrdU
(clone IIB5, Eurodiagnostics, Apeldoorn, The Nether-
lands) and against the proliferation-associated Ki-67 an-
tigen (MIB-1, Immunotech, Marseille, France). In addi-
tion, apoptotic cells were identified by the TUNEL method
(TdT-Kit, Boehringer Technologies, Mannheim, Germa-
ny). Other antibodies used were directed against the
androgen receptor (clone F39.4, kindly provided by Dr.
A. O. Brinkmann, Department of Endocrinology and Re-
production, Erasmus University), the cytoplasmic Bcl-2
antigen (clone 124, Dako, Glostrup, Denmark), and the
neuropeptides bombesin (MoAb 2A11; kindly provided
by Dr. F. Cuttita, National Cancer Institute, Bethesda,
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MD), serotonin (5HT; rabbit polyclonal antibody), vaso-
active intestinal polypeptide (VIP, rabbit polyclonal), and
calcitonin (rabbit polyclonal).
Paraffin-embedded xenograft tissues were cut at 4-mm
sections for single immunostaining and 2 mm for double
immunostaining. The sections were mounted on 3-ami-
nopropyltriethoxysilane-coated glass slides and incubated
overnight at 60°C. The slides were deparaffinized through
xylene and 100% ethanol, and endogenous peroxidase
activity was blocked with 3.3% hydrogen peroxide (H2O2) in
methanol for 10 minutes. After rinsing with tap water and
dest, the slides were placed in 10 mmol/L citrate buffer (pH
6.0). Antigen retrieval was then performed in a microwave at
700 W for an initial 12.5 minutes and a subsequent 5.5
minutes.45 The slides were allowed to cool down to room
temperature and then rinsed with phosphate-buffered sa-
line (PBS). The tissue slides were then put into the Se-
quenza immunostaining system (Shandon, Uncorn, UK). All
slides were preincubated with normal goat serum (DAKO)
diluted 1:10 in PBS, which yields for all primary antibodies
used hereafter, for 15 minutes. The primary antibody was
incubated at the appropriate concentration for 2 hours at
room temperature or overnight at 4°C. The secondary anti-
body was incubated for 30 minutes, being either horserad-
ish-peroxidase-conjugated goat anti-mouse or goat anti-
rabbit (1:50), or biotinylated goat anti-mouse and goat anti-
rabbit (1:400) for monoclonal and polyclonal antibodies,
respectively. In case of biotinylated goat anti-mouse and
goat anti-rabbit, a horseradish peroxidase/streptavidin/bi-
otin complex diluted 1:1:200 in PBS, prepared at least 30
minutes before use, was incubated for a subsequent 30
minutes. Between the subsequent steps, the slides were
rinsed four times with PBS. The bound horseradish peroxi-
dase was visualized in 10 minutes with diaminobenzidine
(Fluka, Neu-Ulm, Germany) in PBS containing 0.075% H2O2
as substrate. Slides were rinsed extensively in tap water
and finally counterstained in Mayer’s hematoxylin, de-
hydrated through a series of alcohol, and embedded in
malinol.
To assess the properties of the NE cells, double stain-
ing of CgA, respectively, with BrdU, MIB-1, androgen
receptor, and Bcl2 was performed on the PC-295 xeno-
graft tumors. The double staining consists of two consec-
utive stainings with two primary antibodies. The first stain-
ing was always a horseradish-peroxidase-related stable
diaminobenzidine complex, whereas the second staining
was performed with an alkaline-phosphatase-conjugated
goat anti-mouse secondary antibody. The alkaline phos-
phatase was visualized after a 30-minute incubation of
the slides with AS-MX-phosphate (0.3 mg/ml; Sigma, St.
Louis, MO) mixed with new fuchsin (2.5 ml/ml; Sigma),
NaNO2 (1.45 mmol/L; Sigma), and levamisole (0.5 mg/ml;
Sigma) in the dark. All compounds were diluted in 0.2
mol/L Tris buffer (Gibco, Life Technologies, Breda, The
Netherlands) adjusted to pH 8.0. In between both stain-
ings, the slides were rinsed with PBS for 1 hour and again
boiled in a microwave in 10 mmol/L citrate buffer (pH 6.0)
for 10 minutes. For immunostaining of incorporated BrdU,
the slides were treated with 2 N HCl at 37°C for 30
minutes to uncoil DNA and subsequently neutralized with
a 0.1 mmol/L sodium tetraborate buffer (pH 8.5). As
negative control, PBS replaced the primary antibody in all
stainings. Radical prostatectomies containing normal
prostatic tissue were used as positive control for CgA,
SGIII, androgen receptor, Bcl-2, and Ki-67 expression.
For all markers, except androgen receptor, the number
of positive cells was determined by quantitative counts of
all cells in tumor squares at 3310 magnification from
which the number of positive cells per square millimeter
was calculated. In total, positive cells were scored as
percentage of the total cell number, in $25 squares. For
the androgen receptor, the level of immunostaining was
assessed semiquantitatively.
Western Analysis
We further confirmed the expression patterns of immuno-
histochemically determined CgA, SGIII, and androgen
receptor in our castration series of PC-295 by Western
immunoblotting. As positive controls, we used material of
human pheochromocytoma for CgA, of rat pituitary for
SGIII, and of the human in vitro cell line LNCaP for andro-
gen receptor expression. The procedure of protein ex-
traction was used as previously described.41 Frozen tis-
sues of the PC-295 xenografts were crushed in a liquid-
nitrogen-chilled metal cylinder. The tissue homogenates
were transferred into a lysis buffer (10 mmol/L Tris (pH
7.4), 150 mmol/L NaCl (Sigma), 1% Triton X-100 (Merck,
Darmstadt, Germany), 1% deoxycholate (Sigma), 0.1%
SDS (Gibco), 5 mmol/L EDTA (Merck), and protease
inhibitors (1 mmol/L phenylmethylsulfonyl fluoride, 1
mmol/L aprotinin, 50 mg/L leupeptin, 1 mmol/L benzami-
dine, and 1 mg/L pepstatin; all from Sigma). After cen-
trifugation of the mixture at 100,000 rpm at 4°C for 10
minutes, the protein content of the supernatants was
measured by the Bradford method (Bio-Rad protein as-
say, Mu¨nchen, Germany).
A 20-mg aliquot of each sample was transferred to an
SDS-polyacrylamide gel, and gel electrophoresis was
performed with prestained markers as size standards
(Novex, San Diego, CA). The gels were blotted to a
0.45-mm cellulose nitrate membrane (Schleicher &
Schuell, Dassel, Germany). The immunoblot was blocked
with PBS (pH 7.7) containing 0.1% Tween-20 (Sigma)
and 5% dry milk for 1 hour. The CgA, androgen receptor,
or SGIII antibodies were added in their optimal concen-
tration and incubated overnight on an orbital shaker at
4°C. After rinsing four times for 15 minutes each with PBS,
incubation for 1 hour was performed with the secondary
horseradish-peroxidase-conjugated antibodies and goat
anti-mouse for mouse monoclonal and goat anti-rabbit for
rabbit polyclonal antibodies, respectively. Subsequently,
a short incubation with a mixture of 10 ml of luminol and
100 ml of oxidizing agent (BM chemiluminescense kit,
Boehringer Mannheim, Mannheim, Germany) followed,
after washing four times for 15 minutes each with PBS.
Excess reagent was removed, and antibodies were visu-
alized by exposure of the blots to an x-ray film.
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Reverse Transcriptase-Polymerase
Chain Reaction
RNA was isolated by using the single-step RNAzol B
method (Campro Scientific, Veenendaal, The Nether-
lands).46 Frozen tissue (100 mg) was homogenized in 1
ml of RNAzol. Chloroform (0.1 ml) was added, and the
mixture was vortexed for 15 seconds followed by a
5-minute incubation on ice. The homogenate was then
centrifuged at 4°C at 12,000 3 g for 15 minutes. The
upper water phase containing the RNA was removed and
mixed with an equal volume of isopropanol. This mixture
was then kept at 4°C for 15 minutes and after that cen-
trifuged at 4°C at 12,000 3 g for 15 minutes. The super-
natant was removed, and the RNA pellet was washed
twice with 75% ethanol by vortexing and centrifugation at
4°C at 12,000 3 g. The pellet was then dried and resus-
pended in sterile H2O. The concentration was deter-
mined at OD 260, and solutions of 1 mg/ml were prepared
for further use in reverse transcriptase polymerase chain
reaction (RT-PCR). The quality of the isolated RNA was
checked by determining the 260/280 ratio and by form-
aldehyde gel electrophoresis to check the ribosomal (28
S and 18 S) bands.
RT-PCR was performed for CgA, SGIII, PAM, PC1 and
-2, and ß2-microglobulin (ß2MG) with a standard proto-
col. The reverse transcriptase reaction was performed
with a master mix containing 5 mmol/L MgCl2, PCR
buffer, 10 mmol/L dNTPs, RNAse inhibitor (10 U), reverse
transcriptase (25 U), 2.5 mmol/L random hexamer prim-
ers, and 0.5 mg of RNA in a total volume of 10 ml covered
with 50 ml of mineral oil. The master mix was then pro-
cessed at 42°C for 60 minutes followed by a 15-minute
incubation at 99°C, and the reaction was stopped at 4°C
for 5 minutes. The cDNA mix that was formed was then
used totally with the master mix of the PCR protocol. In
this protocol, the master mix contained reaction buffer,
Goldstar Red DNA polymerase (Eurogentec, Seraing,
Belgium; 1 U), 15 mmmol/L sense and antisense primer in
a total volume of 40 ml. All samples were first denatured
at 94°C for 10 minutes, and then amplification was per-
formed for 35 cycles of 1 minute at 94°C, 1 minute at
60°C, and 1 minute at 72°C and a final extension at 72°C
for 10 minutes. The PCR product was checked on a 1%
agarose gel and, if necessary, followed by Southern blotting.
Results
A decline in proliferative activity (Figure 1A), a rapid and
persistent loss of androgen receptor expression (Figure
1C), as previously shown for the PC-82 xenograft mod-
el,47 and an increase of apoptosis in the PC-295 human
prostate cancer xenograft is associated with a rapid tu-
mor volume decrease (Figure 1B) after androgen with-
drawal. The percentage of BrdU-incorporating cells after
1 hour of IP administration decreased rapidly from a
basal percentage of 10 in the controls to nearly zero at
day 4 after castration. Accordingly, the MIB-1 expression
decreased from an initial percentage of 20 in the controls
to near zero at day 4 after castration. Within a period of 2
Figure 1. Monitoring of proliferation, apoptosis, NE differentiation, and tu-
mor volume changes in the PC-295 model after androgen withdrawal. A:
Results of the immunohistochemical staining for proliferation (BrdU,  mice
received BrdU IP 1 hour before sacrifice) and MIB-1, E) and neuroendocrine
differentiation (CgA, F). Proliferation is shown in mean percentage of pos-
itive cells scored per 1000 cells (n 5 3), whereas the NE differentiation is
shown as the number of CgA-positive cells per mm3. One-way ANOVA
showed that both BrdU and MIB-1 decreased in time (Kruskal-Wallis, P ,
0.05). At each time point mean values are given (n 5 3). B: Results from
volume measurements () after castration and the immunohistochemical
staining for apoptosis by TUNEL (}). Apoptosis is shown as the percentage
of positive cells scored per 1000 cells. Tumor volume decrease was signifi-
cantly different from controls (t-test, P , 0.05). At each time point mean
values are given (n 5 3).C: Results from prostate-specific antigen serum
measurements (PSA, 1) and immunohistochemical staining for the androgen
receptor (AR, h; scored as percentage/1000 tumor cells) for the different
time points after castration.
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days, the expression of androgen receptor in ;90% of
PC-295 cells disappeared. The percentage of apoptotic
cells increased from the moment of castration to a max-
imum at day 4, when ;20% of the tumor cells were
apoptotic. The PSA serum levels paralleled the dramatic
tumor volume decrease and decreased rapidly after cas-
tration to zero after 7 days (Figure 1C).
Androgen withdrawal also leads to an immediate in-
crease in the proportion of NE cells. The number of NE
cells, as marked by the expression of CgA, increased
from an initial 1,000 cells/mm2 to 60,000 NE cells/mm2 at
day 7 after castration (Figure 1A). The course of CgA
expression in time is given in Figure 2 in which the im-
munostainings of the different time points are shown. The
typical granular staining for CgA increased clearly, and
positive cells were still observed 21 days after castration.
The NE cell was the main tumor cell type found already
from day 7 after castration on, as determined by immu-
nohistochemistry for both CgA and SGIII.
It was clear that the characteristic cribriform growth
pattern of untreated PC-295 tumors disappeared ;4
days after castration, finally resulting in a solid tumor
largely composed of islets of CgA-positive cells sur-
rounded by murine stromal cells. Increased expression of
the neuropeptides serotonin and bombesin was detected
in part of the CgA-positive cells at 7, 14, and 21 days after
castration (data not shown). Increased expression of so-
matostatin receptors was seen 4 and 7 days after cas-
tration, whereas expression of calcitonin or VIP was not
detected. The PC-295 tumor cells showed increased ex-
pression of Bcl-2 from 4 days after castration on. Bcl-2
expression was found in non-NE cells at days 14 and 21
after castration in predominantly CgA- and SGIII-immu-
nostained tumor fields.
Western blot analysis confirmed the immunohisto-
chemical results, showing the increased CgA expression
associated with decreased androgen receptor expres-
sion (Figure 3). The specific CgA 68-kd signal and the
amount of smaller 30-kd CgA-derived peptide clearly
increased after androgen withdrawal, whereas 112-kd
AR expression was clearly lost 2 days after castration.
Increased expression of 63/61-kd SGIII (Figure 4) was
observed from 7 days after castration on. The amounts of
the processed forms of SGIII, as indicated by the 48-,
28-, and 20-kd fragments, decreased after androgen
withdrawal.
Immunohistochemical double labeling of PC-295 tu-
mors clearly showed absence of MIB-1 expression in
CgA-positive cells. For BrdU labeling, however, a differ-
ent result was observed. Tumors of mice injected with
BrdU 1 hour before sacrifice did not show BrdU-labeled
CgA-positive NE cells. Continuously BrdU-labeled tu-
mors, respectively, showed 5% and 10% double-labeled
NE cells at days 2 and 4 after castration, whereas 40%
Figure 2. Immunohistochemical staining for CgA in the PC-295 model at different time points post-castration. A: Control tissue of a poorly differentiated PC-295
tumor with one NE cell. B: PC-295 tumor 1 day after castration with one NE cell (open type). C: PC-295 tumor 2 days after castration with dispersed NE cells. D:
PC-295 tumor 4 days after castration with a cluster of NE cells. E: PC-295 tumor 7 days after castration with a large number of NE cells. F: PC-295 14 days after
castration. G: PC-295 tumor 21 days after castration. H: H&E staining of the PC-295 tumor in the control situation.
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and 70% of the whole cell population was BrdU positive,
respectively.
RT-PCR with human specific CgA and SGIII primers
demonstrated a clear increase of the NE phenotype in
PC-295 after 4 days of androgen withdrawal by using
b2MG expression as internal human control (Figure 5).
No significant variation in PAM expression was noted
after castration.
Discussion
In this report, we extend the previous observations done
in the PC-295 human prostate cancer xenograft model
and describe in more detail the characteristics of NE
differentiation in prostate cancer under hormonal regula-
tion. The growth and regression of the PC-295 human
prostate cancer xenograft in the presently described cas-
tration experiment was comparable to the result of earlier
studies performed with this model.40 The tumor doubling
time was 13 days, and the half-life time of tumors after
castration was 4.3 days, which was within the same
range as found in earlier experiments. After 21 days of
androgen withdrawal, only 10% of the initial tumors (200
instead of 2000 mm3) was left, so the PC-295 tumor
model regressed rapidly after androgen withdrawal. Both
Western blot analysis and immunohistochemistry showed
a rapid decrease in androgen receptor expression in the
PC-295 tumors,41 comparable to the behavior of the fully
androgen-dependent human PC-82 xenograft after cas-
tration.47 This was paralleled by a clear and rapid de-
crease of the PSA serum levels, clearly demonstrating the
androgen-dependent character of the PC-295 model.
The immunohistochemical results showed a rapid de-
crease of BrdU- and MIB-1-positive cells from 10% and
20% in the controls to ;0% in tumors at days 4 and 7,
respectively. Both nuclear proliferation markers showed a
50% decrease 2 days after castration. The TUNEL stain-
ing for apoptosis showed a maximum of apoptotic cells at
4 days after castration. The NE phenotype was clearly
and rapidly induced at 4 days after androgen withdrawal,
at which time point there were only a few proliferating
cells left.
Analysis for CgA by Western and RT-PCR confirmed
the increased expression of the CgA protein and RNA in
time from a basal expression level in the controls to a
maximum at 7 and 14 days after castration. There is
considerable variation in the basal level of NE cells in the
androgen-supplemented situation, which could be ex-
plained by an inter-tumor variation between different
mice, which seems to be associated with environmental,
eg, host-derived factors, rather than due to an intrinsic
tissue heterogeneity. Expression levels of the NE pheno-
type in the different tumors were confirmed by comparing
the immunohistochemical picture with the Western and
RT-PCR data at the different time points. Despite inter-
tumor differences in CgA expression levels at the mo-
Figure 3. Expression of the androgen receptor (AR) and Chromogranin A
(CgA) in the PC-295 model following androgen withdrawl analyzed by
Western blotting. Both panels show the time points T0, T20.5, T21,T21.5, T22,
T24, and T27. In the upper panel the decreasing signal of androgen receptor
expression is found at 110-112 kd. The CgA signal can be found between 66
and 75 kd in the lower panel, which are the lowest bands in the control
Pheochromocytoma (Pheo). Both panels also show the processed proteins or
degradation products.
Figure 4. Expression of Secretogranin III in the PC-295 model following
androgen withdrawl analyzed by Western blotting. Secretogranin III is ex-
pressed as 63/61 kd (upper arrow) double band in prostate carcinoma
(PrCa), pituitary (rat), and in the PC-295 models at all indicated time points.
The processed forms of the protein are also visible at the lower bands of 48
kd, 28 kd, and 20 kd (compare the pituitary lane).
Figure 5. Results of RT-PCR for NE markers in the PC-295 model post
castration. Expression patterns of CgA, SGIII, b2MG, and PAM are shown for
different time points in the tumor after castration. Lengths of the PCR prod-
ucts are given. H69 is a small cell lung cancer cell line, and 2RT and w are
controls for reverse transcriptase and water, respectively.
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ment of castration, a clear increase in the mean value of
NE differentiation was observed 4, 7, and 14 days after
castration. RT-PCR analysis showed that expression of
CgA mRNA initially decreased after androgen with-
drawal, after which it increased again after day 4 when
the tumor cells did not proliferate. The difference be-
tween immunohistochemistry and RT-PCR from day 0 to
day 4 is most likely caused by inter-tumor variation in
basal CgA expression levels. Another explanation is that
the levels of CgA mRNA are higher in NE cells of the
controls compared with NE cells directly after androgen
withdrawal.
The induction of NE differentiation after androgen with-
drawal has now clearly been shown. To further charac-
terize NE cells and the process of NE differentiation we
are testing other and possible early markers of NE differ-
entiation. In the PC-295 model, we detected increased
expression of SGIII at both the protein level by Western
blotting and immunohistochemistry and at mRNA level as
determined by RT-PCR analysis. This clearly indicates
that the regulated secretory pathway (RSP) is active in
these prostatic NE cells. Holthuis et al were able to clone
the various components of the genetic route of the RSP in
Xenopus laevis29 and found several NE markers that are
co-expressed with SGIII, such as Ac45 and X7365 for the
RSP. The expression of CgA is not a requisite for regu-
lated secretion of bioactive neuropeptides, as CgA is just
a general marker for NE cells and not functionally in-
volved. It will be relevant to study RSP-related proteins,
such as SGIII and PC1, which are currently being stud-
ied, to establish whether neuropeptides can be actively
secreted by NE cells in the PC-295 model.
No changes in the PC-295 model were found in PAM
mRNA expression levels as determined by RT-PCR. PAM
was expressed as three splice variants, which was similar
to the expression pattern of PAM in lung cancer cell
lines.33 PAM is not necessarily expressed in NE cells, as
it is a protein that activates neuropeptides by amidation
after their secretion from NE cells. It is therefore not
surprising that the expression of PAM did not increase in
the PC-295 model after castration.
Serotonin and bombesin, but not VIP and calcitonin,
were expressed in the PC-295 model. Using somatostatin
(ss) autoradiography by [125I-TYR0]SS-28, which binds
with high affinity to the five known somatostatin-receptor
subtypes, specific binding was demonstrated for ss re-
ceptors type sst1 and sst2 in PC-295 tumor tissue (L.
Hofland, Department of Internal Medicine, Erasmus Uni-
versity, unpublished results). These results indicate that a
number of growth-modulating neuropeptides and some
of their receptors can play a role in the PC-295 model.
From the double stainings of CgA with BrdU and
MIB-1, it was concluded that the greater part of the NE
cells was in the G0 phase of the cell cycle, which was in
agreement with other studies on prostate cancer.22,23
From the double-labeling studies with MIB-1 and CgA it
was seen that the few proliferating cells at 7 days after
castration were surrounding the predominantly CgA-pos-
itive islets of the PC-295 human prostate cancer tissue.
Subsequently, comparing the Western blot results for
CgA and androgen receptor clearly showed that the NE
cells did not express the androgen receptor. NE cells
thus seem to be an androgen-independent, nonprolifer-
ating part of the prostatic epithelium.
Bonkhoff et al predominantly found in benign prostatic
glands that proliferation was restricted to the prostatic
basal cell layer and that basal cells did not express the
androgen receptor. In prostate cancer specimens, an-
drogen-receptor-negative NE cells expressed cytokera-
tin 18 and 5, and these cells were found in the proximity
of proliferating cells. In the PC-295 experimental tumor
model, clustered NE cells are thus also found in the
proximity of proliferating cells, indicating a possible inter-
action between NE cells or their products and neighbor-
ing proliferating cells. The fact that basal, proliferating
cells and CgA-positive NE cells are the only cells surviv-
ing androgen deprivation suggests that the absence of
androgen receptor expression plays a key role in their
survival. Another factor for cellular survival is Bcl-2, which
protects cells from undergoing apoptosis. This is also
shown in our model as Bcl-2 expression increases after
androgen withdrawal. After castration, Bcl-2 is not ex-
pressed in NE cells but in a proportion of non-NE putative
androgen-independent cells in the PC-295 xenograft. In a
recent publication,16 Xue et al showed a specific keratin
expression pattern for most NE cells in prostate cancer
patient material by using serotonin as a NE marker com-
bined with the luminal epithelial cell marker (cytokeratin
18) and a typical basal cell marker (cytokeratin 5, RCK
103). A minority of the prostatic NE cells expressed only
cytokeratins for basal cells or luminal cells. NE cells thus
form a heterogeneous population. However, no expres-
sion of Bcl-2 in NE cells in patient material was found,
suggesting that Bcl-2 expression is lost during NE differ-
entiation of Bcl-2-positive basal cells.16 In the in vivo
model LuCaP, cell lineage markers PSA, neuron-specific
enolase (NSE), and Bcl-2 were used to mark the different
epithelial cell types found in prostate cancer tissue.39
They proposed a model in which Bcl-2-positive prolifer-
ating epithelial cells differentiated into either a lineage of
NSE-expressing NE cells or a lineage of PSA-expressing
exocrine secretory cells. In this latter population, the ex-
pression of NSE is heterogeneous. These amphicrine, ie,
both NSE- and PSA-positive, cells may be induced to
express Bcl-2, which might result in tumor cells surviving
hormonal manipulation. These results partly support the
stem cell model for benign prostatic hyperplasia proposed
by Isaacs and Coffey.48 They propose a model of prostatic
stem cells, which divide into a limited number of amplifying,
basal cells followed by a limited number of cell divisions to
finally form transit cells that differentiate into the different
epithelial cell subpopulations. In prostate cancer, most
probably the amplifying step in this model is not limiting,
resulting in numerous types of exocrine and endocrine cells
expressing different combinations of cytokeratins.
In the PC-295 model, we found BrdU-positive NE cells.
As we did not find MIB-1 expression in NE cells, we
believe that the NE cells did not proliferate, but rather that
a fraction of CgA-positive cells entered S phase shortly
after castration. It is supposed that such cells are ar-
rested before mitosis. Another more plausible explana-
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tion is that the BrdU-labeled cells were amplified after
castration and differentiated into NE cells in the time that
followed between BrdU labeling and sacrifice at day 2 or
4 after castration. Considering Xue et al and the present
results, there are possibly two routes of NE differentiation
in androgen-dependent epithelia: a regular route from
proliferating cells via an intermediate cell type to NE cells
and an alternative route of induced NE differentiation
from exocrine luminal cells by androgen withdrawal.
The CgA and SGIII staining, the increased apoptosis,
and the nonproliferative status of most of the NE cells
seen in the controls (T0) and at 7 days after castration in
the currently described PC-295 xenograft clearly show
the process of neuroendocrine differentiation as being
induced by androgen withdrawal. From the histological
picture it is also clear that the changes in NE expression
are not due to a selection of NE cells. The BrdU-positive
NE cells are probably the best indicators of the post-
castration amplified cells that differentiate into a NE cell.
The greater part of the NE cells found after 4 days of
androgen withdrawal differentiated from G0-phase-ar-
rested luminal or intermediate cells. Clearly, the induction
of the NE phenotype is a proliferation-independent pro-
cess in the PC-295 model. PC-295 tumors did not grow
without androgens either in female mice or after long-
term castration of PC-295 tumor-bearing mice (data not
shown). This may be explained by the rapid decrease in
proliferation and the rapid tumor regression of the PC-295
tissue after castration. Probably, the decreased tumor
vascularity in PC-295, observed after prolonged andro-
gen withdrawal, caused the death of surviving nonprolif-
erating cells. All together, neither the induction of the NE
phenotype nor Bcl-2 expression of non-NE cells after
castration in PC-295 led to androgen-independent
growth or maintenance of the tumor vascularity.
As the prognostic value of CgA expression or occur-
rence of NE differentiation in prostate cancer is still under
debate, additional testing of SGIII and PAM as possible
better NE-related prognostic markers for the progression
of prostate cancer is still relevant. Possible changes in
expression of components of the regulated secretory
pathway or PAM might have effects on, for example,
overproduction of bioactive growth-stimulating neu-
ropeptides.
The PC-295 in vivo model is a potential model for ad-
ditional studies of the induction of NE differentiation by
androgen withdrawal, the regulated secretory pathway in
particular. In addition, PC-310, another androgen-depen-
dent, NE differentiated prostate cancer model, is cur-
rently under investigation and might provide us with ad-
ditional knowledge on NE differentiation. Differentiation of
NE cells from basal or luminal cells and the role of NE
cells in progression of prostate cancer are important
aspects to be studied as well. SGIII, PAM, or other mark-
ers for NE differentiation are to be tested retrospectively
for their prognostic value in the survival of patients un-
dergoing radical prostatectomies. Human prostate can-
cer xenograft models with NE differentiation will be used
to answer fundamental questions on prostate cancer.
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